Recruiting NCT07154134

Endocan and Copeptin Serum Levels in Preterm Neonates With Respiratory Distress Syndrome

Trial Parameters

Condition Endocan

Sponsor Tanta University

Study Type OBSERVATIONAL

Phase N/A

Enrollment 40

Sex ALL

Min Age 28 Weeks

Max Age 36 Weeks

Start Date 2025-07-10

Completion 2025-11-01

All Conditions

Endocan Copeptin Serum Preterm Neonates Respiratory Distress Syndrome

Interventions

Serum endocanSerum copeptin

Brief Summary

This work aims to investigate and compare the levels of serum endocan and serum copeptin on the first day of life and correlate their levels to the severity of respiratory distress in preterm neonates suffering from respiratory distress syndrome.

Eligibility Criteria

Inclusion Criteria: * Prematurity. * Gestational age between 28 and 36 weeks. * Suffering from respiratory distress syndrome. Exclusion Criteria: * Intrauterine growth restriction (IUGR). * Hypoxic ischemic encephalopathy. * Multiple congenital anomalies. * Chromosomal abnormalities. * Preterm less than 28 weeks. * Neonates with a maternal history of chorioamnionitis (early sepsis). * Infant of diabetic mother. * Prelabor rupture of membranes (PROM)\> 2 hours.

Related Trials

NCT07154134

Endocan and Copeptin Serum Levels in Preterm Neonates With Respiratory Distress Syndrome

View Trial →

VIEW ON CLINICALTRIALS.GOV ↗ MORE ENDOCAN TRIALS